Custom Synthesis Revenue Mix
57%
+2pp YoY
CS segment contributed 57% of total sales in Q3, up from 55% in the same quarter last year, reflecting strong demand.
DIVISLAB
Diversified
15 Jan 2026
Divislab Ltd — Q3 FY26
Divis Laboratories reported Q3 FY26 consolidated total income of INR 2,692 crore, up 12% YoY, driven by strong custom synthesis (57% mix) and stable generics volume.
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Divis Laboratories reported Q3 FY26 consolidated total income of INR 2,692 crore, up 12% YoY, driven by strong custom synthesis (57% mix) and stable generics volume. PAT stood at INR 583 crore, flat YoY due to a one-time exceptional item of INR 74 crore from labour code changes. Gross margins improved sharply to 63.7% (material consumption 36.3% of sales vs 39.8% last year) on favourable product mix. Management highlighted three dedicated CS projects progressing towards commercialization by Q3-Q4 CY2027, with validations ongoing. Peptide capabilities advanced with a dedicated commercial building for SPPS. Nutraceuticals contributed INR 214 crore in the quarter. Risks include continued generic pricing pressure and potential input cost impact from China's export tax rebate withdrawal. Overall, the company is well-positioned for double-digit growth with a strong pipeline and capacity expansion.
डिविस लैबोरेटरीज ने वित्त वर्ष 2025-26 की तीसरी तिमाही में कुल आय 2,692 करोड़ रुपये दर्ज की, जो पिछले साल से 12% अधिक है। यह वृद्धि मुख्य रूप से कस्टम सिंथेसिस (57% हिस्सेदारी) और जेनेरिक दवाओं की स्थिर बिक्री से हुई। कंपनी का मुनाफा 583 करोड़ रुपये रहा, जो पिछले साल के बराबर है। इसमें एक बार का 74 करोड़ रुपये का खर्च शामिल है, जो मजदूरी नियमों में बदलाव के कारण हुआ। कच्चे माल की लागत घटने से कंपनी का मुनाफा मार्जिन 63.7% हो गया। प्रबंधन ने बताया कि तीन नए कस्टम सिंथेसिस प्रोजेक्ट 2027 के अंत तक शुरू होंगे। पेप्टाइड तकनीक में भी प्रगति हुई है। न्यूट्रास्युटिकल्स से तिमाही में 214 करोड़ रुपये की आय हुई। जोखिमों में जेनेरिक दवाओं पर दबाव और चीन से आयात पर संभावित असर शामिल है। कुल मिलाकर, कंपनी मजबूत स्थिति में है।
Key Numbers
Nutraceutical Revenue
INR 214 crore
+11% YoY
Nutraceuticals segment grew to INR 214 crore in Q3, with healthy momentum expected to continue.
Capacity Utilization
70-80%
Stable
Overall capacity utilization ranged between 70-80% during the quarter, varying by month and shipment schedules.
Domestic Supplier Base
78%
+N/A
Procurement from domestic suppliers increased to 78% of total, reducing dependence on China and mitigating supply chain risks.
What Changed vs Last Quarter
NEW
Double-digit revenue growth trajectory maintained
Management reiterated expectation of double-digit constant currency growth, supported by a balanced pipeline across patent phases.
NEW
Phase two expansion at Kakinada under evaluation
Company is evaluating a second phase expansion at Unit 3 with 4 additional production blocks, but no final decision or timeline announced.
UPDATED
Three dedicated CS projects to commercialize by Q3-Q4 CY2027
Three custom synthesis molecules currently in validation/regulatory approval stages are expected to start commercial volumes in the second half of calendar year 2027.
DROPPED
FY26 CapEx to exceed INR 2,000 crore
Management confirmed that FY26 CapEx will be higher than the earlier guidance of INR 2,000 crore, driven by three new projects with long-term supply commitments.
DROPPED
Constant currency revenue growth ~10.8% for H2
Management expects constant currency revenue growth for the second half to be similar to H1's 10.79%.
NEW RISK
China export tax rebate withdrawal may increase input costs
China's removal of export tax rebates on certain chemicals could lead to selective pricing pressures on raw materials, though company has diversified 78% of procurement domestically.
NEW RISK
Concentration risk in peptide segment
Peptide capacity is largely dedicated to a single customer's requirements, creating dependency; management declined to disclose details on diversification.
RISK GONE
Margin impact from product mix shift
Despite higher CS mix, overall margins have remained stable, suggesting limited upside from mix improvement due to generic pricing pressure.
RISK GONE
Confidentiality limits visibility on new projects
Management declined to provide details on peptide capacity, margins, or specific project timelines, creating uncertainty for investors.
🤫 Topics management stopped discussing
Mentioned in Q1 FY25, Q2 FY25, Q3 FY25, Q4 FY25
Extended lead times of 2-3 weeks due to Red Sea rerouting are increasing freight costs and complicating supply chain planning.
Mentioned in Q1 FY26, Q2 FY26
Management confirmed that FY26 CapEx will be higher than the earlier guidance of INR 2,000 crore, driven by three new projects with long-term supply commitments.
Mentioned in Q1 FY25, Q2 FY25
Total capital expenditure for FY25, including Kakinada, is expected to be around INR 1,600 crores, with INR 1,000 crores remaining to be spent.
Mentioned in Q1 FY25, Q3 FY25
Ongoing price erosion in generics continues to pressure revenue growth despite volume increases.
Management Guidance
Three dedicated CS projects to commercialize by Q3-Q4 CY2027
Three custom synthesis molecules currently in validation/regulatory approval stages are expected to start commercial volumes in the second half of calendar year 2027.
Management guidance revenueDouble-digit revenue growth trajectory maintained
Management reiterated expectation of double-digit constant currency growth, supported by a balanced pipeline across patent phases.
Management guidance growthPhase two expansion at Kakinada under evaluation
Company is evaluating a second phase expansion at Unit 3 with 4 additional production blocks, but no final decision or timeline announced.
Management guidance capexKey Risks
Generic pricing pressure persists
Pricing environment for generics remains competitive, limiting value growth despite volume increases.
medium · management_commentaryChina export tax rebate withdrawal may increase input costs
China's removal of export tax rebates on certain chemicals could lead to selective pricing pressures on raw materials, though company has diversified 78% of procurement domestically.
medium · management_commentaryRegulatory approval delays for CS projects
Commercialization of three dedicated CS projects depends on customer regulatory approvals, which could face delays beyond the guided Q3-Q4 CY2027 timeline.
medium · analyst_questionConcentration risk in peptide segment
Peptide capacity is largely dedicated to a single customer's requirements, creating dependency; management declined to disclose details on diversification.
medium · data_observationNotable Quotes
The sky is the limit for you to dream.
We do not foresee any disruption because, and it's in line with whatever our double-digit growth that we keep talking about.
We are not hedging. We are evaluating at this point based on the overall scenario in the market.
Frequently Asked Questions
What was Divislab's revenue in Q3 FY26?
Divislab reported revenue of ₹2,692 Cr in Q3 FY26, representing a +12.1% change compared to the same quarter last year.
What guidance did Divislab management give for FY27?
Three dedicated CS projects to commercialize by Q3-Q4 CY2027: Three custom synthesis molecules currently in validation/regulatory approval stages are expected to start commercial volumes in the second half of calendar year 2027. Double-digit revenue growth trajectory maintained: Management reiterated expectation of double-digit constant currency growth, supported by a balanced pipeline across patent phases. Phase two expansion at Kakinada under evaluation: Company is evaluating a second phase expansion at Unit 3 with 4 additional production blocks, but no final decision or timeline announced.
What are the key risks for Divislab in FY27?
Key risks include Generic pricing pressure persists — Pricing environment for generics remains competitive, limiting value growth despite volume increases.; China export tax rebate withdrawal may increase input costs — China's removal of export tax rebates on certain chemicals could lead to selective pricing pressures on raw materials, though company has diversified 78% of procurement domestically.; Regulatory approval delays for CS projects — Commercialization of three dedicated CS projects depends on customer regulatory approvals, which could face delays beyond the guided Q3-Q4 CY2027 timeline.; Concentration risk in peptide segment — Peptide capacity is largely dedicated to a single customer's requirements, creating dependency; management declined to disclose details on diversification..
Did Divislab meet its previous quarter's guidance?
Of 2 tracked promises, management 0 met, 0 close, 2 missed.
Where can I read the full Divislab Q3 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.